Analytical Data
-
基因名
IFN-omega 1
- Application
-
别名
IFNW1; IFNW; Interferon omega-1; IFN-omega-c1; Interferon alpha-II-1
-
种属
Bovine
-
表达系统
E. coli
-
标签
N-6*His;N-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P07352
-
表达区间
C24-P195
-
蛋白长度
Full Length of Mature Protein
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon omega 1 (IFN-ω1) is a type I interferon that has garnered attention for its potential therapeutic applications in various diseases, particularly infectious diseases and cancer. As a cytokine, IFN-ω1 plays a crucial role in the immune response by mediating antiviral activities, promoting cellular proliferation, and enhancing the immune system's ability to detect and eliminate pathogens. Unlike other interferons, IFN-ω1 is primarily produced by leukocytes and exhibits a unique receptor binding profile, which may result in distinct signaling pathways and biological effects. Research on recombinant IFN-ω1 focuses on its production, characterization, and functional studies to better understand its role in immunomodulation. Additionally, studies have explored its potential to treat conditions such as chronic viral infections (e.g., hepatitis) and certain types of cancers, leveraging its ability to induce antiviral states and modulate immune responses. Investigators are also examining the safety, efficacy, and optimal dosing regimens of IFN-ω1 in clinical settings, as well as its interactions with other therapeutic agents. Overall, the study of recombinant IFN-ω1 is pivotal in enhancing our understanding of immune regulation and developing novel therapeutic strategies for diseases with high unmet medical needs.
